AIM ImmunoTech Publishes Early Access Data in Prestigious Oncology Journal
Immuno-pharma company, AIM ImmunoTech (NYSE American: AIM) has published a new data analysis from a long-term Early Access Program studying the company’s drug Ampligen® (rintatolimod) for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC).
The company’s research, titled, “Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses,” appears in the prestigious oncology journal, Clinical Cancer Research.
AIM Chief Executive Officer, Thomas K. Equels, said, “We have already seen that Ampligen as a single-agent therapy was associated with improved progression-free survival and overall survival in these Early Access Program pancreatic cancer patients. This new data analysis provides us further insight into exactly why that’s the case, which could give us the ability to identify cancer patients who might benefit more from Ampligen treatment than they would from other known cancer treatments.”
Based on the results, AIM believes that Ampligen may break immunological tolerance by enhancing anti-tumor immunity through DC-mediated T-cell responses.
AIM is currently evaluating Ampligen as a therapy for metastatic pancreatic ductal adenocarcinoma in the Phase 1b/2 DURIPANC clinical study, and as a therapy for locally advanced pancreatic adenocarcinoma in the Phase 2 AMP-270 clinical study.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
